- Home
- CING vs ANVS Comparison
CING vs ANVS Comparison
Compare CING & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CING | ANVS |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | 13 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.1M | 111.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CING | ANVS |
|---|---|---|
| Price | $6.69 | $2.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $37.00 | $13.50 |
| AVG Volume (30 Days) | ★ 618.4K | 382.0K |
| Earning Date | 03-18-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.20 | $1.11 |
| 52 Week High | $11.89 | $5.50 |
Technical Indicators
Market Signals| Indicator | CING | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 42.74 |
| Support Level | $3.77 | $2.29 |
| Resistance Level | $7.92 | $2.99 |
| Average True Range (ATR) | 1.08 | 0.22 |
| MACD | -0.23 | -0.00 |
| Stochastic Oscillator | 10.24 | 14.68 |
Price Performance
Historical ComparisonAbout CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.